Supplementary Tables 1-16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma

Supplementary Table 1: Atomic modelling, refinement, and validation statistics. Supplementary Table 2: Cryo-EM data collection and image analysis. Supplementary Table 3: Lymphoma cell lines evaluated in golcadomide study. Supplementary Table 4: Densitometry-based quantification of protein expression of selected markers within DLBCL cell line panel. Supplementary Table 5: Summary of the IC50 and proliferation AUC of lymphoma cell lines treated with golcadomide or other compounds. Supplementary Table 6: Genes with a significant modulation and temporal pattern in the golcadomide sensitive models. Supplementary Table 7: Pathway analysis of genes enriched for interferon signalling and immune system. Supplementary Table 8: BioMAP diversity plus panel result of golcadomide. Supplementary Table 9: Tissue distribution profile in rats treated with 10 mg/kg golcadomide. Supplementary Table 10: Plasma and brain pharmacokinetics of golcadomide in the OCI-Ly10 central nervous system lymphoma model. Supplementary Table 11. List of golcadomide enriched or depleted genes (FDR <= 0.05) in SU-DHL-4 CRISPR screen. Supplemental Table 12: Summary of apoptosis and proliferation of lymphoma cell lines treated with single agent or in combination with golcadomide. Supplementary Table 13: Summary of synergy score and max synergy area from the golcadomide combination therapies. Supplementary Table 14: Gene enrichment scores of FACS competition assays in DLBCL cell lines with golcadomide treatment. Supplementary Table 15: List of antibodies. Supplementary Table 16: List of genes and guide sequences used for CRISPR-Cas9 knockout assay and genome wide CRISPR screen.